Relevance of SARS-CoV-2 related factors ACE2 and TMPRSS2 expressions in gastrointestinal tissue with pathogenesis of digestive symptoms, diabetes-associated mortality, and disease recurrence in COVID-19 patients

  1. Ashutosh Kumar
  2. Muneeb A. Faiq
  3. Vikas Pareek
  4. Khursheed Raza
  5. Ravi K. Narayan
  6. Pranav Prasoon
  7. Pavan Kumar
  8. Maheswari Kulandhasamy
  9. Chiman Kumari
  10. Kamla Kant
  11. Himanshu N. Singh
  12. Rizwana Qadri
  13. Sada N. Pandey
  14. Santosh Kumar

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.mehy.2020.110271
  2. Version published to 10.1101/2020.04.14.040204v2 on bioRxiv
  3. ScreenIT

    SciScore for 10.1101/2020.04.14.040204: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementIACUC: Since no direct subject or patient data were used in this study, clearance from the Institutional Ethics Committee was precluded.
    IRB: IHC: As described by the source labs, specimens containing normal tissue were collected and sampled from anonymized paraffin embedded material of surgical specimens, in accordance with approval from the local ethics committee.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Antibodies against human ACE2 (HPA000288, CAB026174) and TMPRSS2 (HPA035787) were labeled with DAB (3, 3’-diaminobenzidine) stain.
    human ACE2
    suggested: (Sigma-Aldrich Cat# HPA000288, RRID:AB_1078160)
    CAB026174
    suggested: None
    TMPRSS2
    suggested: (Sigma-Aldrich Cat# HPA035787, RRID:AB_2674782)
    HPA035787
    suggested: None
    Software and Algorithms
    SentencesResources
    A digestive system specific functional enrichment map of ACE2 gene was constructed using g:profiler (https://biit.cs.ut.ee/gprofiler/gost) utility and viewed with Cytoscape software, version 3.7.2 (https://cytoscape.org/).
    g:profiler
    suggested: (G:Profiler, RRID:SCR_006809)
    Cytoscape
    suggested: (Cytoscape, RRID:SCR_003032)
    https://cytoscape.org/
    suggested: (CluePedia Cytoscape plugin, RRID:SCR_015784)
    The extracted RNA samples were analyzed using either an Experion automated electrophoresis system (Bio-Rad Laboratories, Hercules, CA, USA) with the standard-sensitivity RNA chip or an Agilent 2100 Bioanalyzer system (Agilent Biotechnologies, Palo Alto, USA) with the RNA 6000 Nano Labchip Kit.
    Bio-Rad Laboratories
    suggested: (Bio-Rad Laboratories, RRID:SCR_008426)
    Agilent Biotechnologies
    suggested: None
    Transcript abundance estimation was performed using Kallisto v0.43.1 (https://pachterlab.github.io/kallisto/about).
    Kallisto
    suggested: (kallisto, RRID:SCR_016582)

    Results from OddPub: Thank you for sharing your data.

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    Limitations: All the aspects of the plausible SARS-CoV-2 binding receptor ACE2 mediated pathology in the digestive system which we have discussed above are based on the distribution of the virus cell entry related factors in the normal tissue. Hence, this study presents indirect evidence which needs to be validated in actual patients before reaching any conclusion. Future directions: Further studies are advisable to understand the molecular mechanisms involved in the SARS-CoV-2 binding receptor ACE2 mediated dysregulation of the intestinal nutrient transporters and finding out COVID-19 specific drug targets. Inter-individual variations in frequency of the digestive symptoms, diabetes associated mortality, and recurrences may depend upon the genotype specific variations in ACE2 expression and other patient specific characteristics (like age, sex, and comorbidity). A study of these variables in the disease pathogenesis may help in deciding personalized therapeutic management for the COVID-19 cases.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  4. Version published to 10.1101/2020.04.14.040204v1 on bioRxiv